NEW YORK (GenomeWeb) – Veracyte has entered into a co-promotion agreement with Genzyme for the Afirma Gene Expression Classifier test in Brazil and Singapore, according to the firm's Form 10-K recently filed with the US Securities and Exchange Commission.

Under the terms of the agreement, Veracyte will pay Genzyme 25 percent of cash receipts from the sale of the Afirma GEC test in Brazil and Singapore over a five-year period that began on Jan. 1, 2015.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.